Evidence map›Paper›PMID 29784587›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2018

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Marco Ruella, Carl H June

Abstract readComment
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  6. Review
  7. Article
  8. Review
  9. Emerging Cellular Therapies for Cancer.Annual review of immunology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Marco RuellaCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA.
Carl H JuneCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA. Electronic address: cjune@upenn.edu.

Funding

Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8M
IMMUNOTHERAPY WITH CAR T CELLSR01CA120409 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H., ZHAO, YANGBING · 2006 to 2016
$2.7M
Resistance To Targeted Immunotherapies:CART19 as a ParadigmR00CA212302 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUELLA, MARCO · 2018 to 2020
$608k
Resistance To Targeted Immunotherapies:CART19 as a ParadigmK99CA212302 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUELLA, MARCO · 2017 to 2018
$348k
NCI NIH HHS K99 CA212302NCI NIH HHS P01 CA214278NCI NIH HHS R00 CA212302NCI NIH HHS R01 CA120409
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CD19AnimalsB-LymphocytesHumansMiceMice, TransgenicT-LymphocytesAntigens, CD19

Identifiers

PMID29784587
PMCPMC5986966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.